Clinical Study
Testing a Study Drug TAK-755 for People with Idiopathic Thrombocytopenic Purpura (iTTP)
Idiopathic Thrombocytopenic Purpura (iTTP) is a blood disease that leads to organ failure in the body. The study will test a drug called TAK-755 to treat adults with this disease. The study mainly wants to see if the drug will help people with this disease and is safe. People in the study will be randomly chosen to be treated with a different dose strength of the study drug TAK-755. Being in the study requires attending a various number of study visits at the clinic depending on the phase of study participation. Medical tests will be done during the study to track the health of the participants.
For more information contact:
June Lee
june.h.lee@hsc.utah.edu
801-587-7759
IRB#: IRB_00169901
| PI: Mouhamed Yazan Abou-Ismail
| Department: HEMATOLOGY\BMT
| Approval Date: 2024-04-24 06:00:00
Specialties: Hematology/BMT
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- 18 years or older
- Diagnosis at the beginning of iTTP or relapsed based on certain criteria: 1)Thrombocytopenia (low amount of white blood cells that helps the blood clot) 2) Microangiopathic hemolytic anemia (an issue in the blood that causes the loss of red blood cells)
- Able to attend in-person
Exclusion Criteria:
- Diagnosed with cTTP (another blood disease) or another cause of TMA (a blood disease)
- Received caplacizumab (a drug used to help the disease) within 30 days before participation
- An iTTP event within the past 30 days before participation
Will I be paid for my time?
Yes